anhwestmacott
/
anh1997
1
0
Code Issues Packages Projects Wiki

Add TRT and BPH: Can You Boost Testosterone Without Worsening Your Prostate?

Anh Westmacott 2026-04-02 22:18:14 +08:00
commit 146047622a
1 changed files with 8 additions and 0 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

8
TRT-and-BPH%3A-Can-You-Boost-Testosterone-Without-Worsening-Your-Prostate%3F.md Normal file

@ -0,0 +1,8 @@
<br>
<br>This idea came from early studies in the 1940s and 1950s. DHT is made from [buy testosterone online no prescription](http://47.104.60.158:7777/samiradeegan0) by an enzyme called 5-alpha reductase. The concern is not just about [testosterone store](https://git.miasma-os.com/paulettesides) alone, but how it turns into another hormone called dihydrotestosterone (DHT). It also plays a role in prostate development during puberty. But more recent studies show a more complex and balanced view. As more men consider TRT for low [buy testosterone powder](https://es-africa.com/employer/store/), it’s important to understand how often BPH occurs and how the two conditions can affect each other. Still, there are risks, [hellomusic.app](https://hellomusic.app/wadegrady80521) and careful monitoring is important.
Regular vigorous exercise may reduce one's chance of developing advanced prostate cancer, as can several dietary interventions. In contrast to men of African descent, East Asian men have among the lowest rates of prostate cancer globally. Together, known gene variants are estimated to cause around 25% of prostate cancer cases, including 40% of early-onset prostate cancers.
Less commonly, tumors have aberrant activation of the Wnt signaling pathway via disruption of members APC (9% of tumors) or CTNNB1 (4% of tumors); or dysregulation of the PI3K pathway via PI3KCA/PI3KCB mutations (6% of tumors) or AKT1 (2% of tumors). Many of these mutations are in genes that protect from DNA damage, such as p53 (mutated in 8% of localized tumors, more than 27% of metastatic ones) and RB1 (1% of localized tumors, more than 5% of metastatic ones). These mutations affect genes involved in cell growth, replication, cell death, and [git.suzk.ru](https://git.suzk.ru/fhvkimberly125) DNA damage repair. Prostate cancer is caused by the accumulation of genetic mutations to the DNA of cells in the prostate. Restlessness is also common, sometimes caused by physical discomfort from constipation or urinary retention, sometimes caused by anxiety. Inflammation in the spine can be treated with high-dose steroids, as well as surgery and radiotherapy to shrink spinal tumors and relieve pressure on the spinal cord.
If cancer is present, [movieru.jp](https://movieru.jp/portfolio/@sherriperez453?page=about) the pathologist assigns a Gleason score; a higher score represents a more dangerous tumor. Below are frequently asked questions regarding prostate enlargement. This is because early treatment of BPH can be vital in reducing the condition’s effect on a person’s wellbeing. Early diagnosis can be important as early treatment can minimize the effects of BPH. If a person has a high risk of BPH, it is best to speak with a doctor.
Prostate cancer is the most diagnosed cancer in men in more than half of the world's countries, and the leading cause of cancer death in men in around a quarter of countries. Prostate cancer is the second-most frequently diagnosed cancer in men, and the second-most frequent cause of cancer death in men (after lung cancer). Similarly, deletions of the tumor suppressor PTEN are harbored by 12–17% of castrate-sensitive tumors, but more than 40% of castrate-resistant tumors.
The prognosis of diagnosed prostate cancer varies widely based on the cancer's grade and stage at the time of diagnosis; those with lower stage disease have vastly improved prognoses. Other bone modifying agents like zoledronic acid and denosumab can reduce prostate cancer bone pain, even though they have little effect on tumor size. Similarly, the systemic chemotherapeutics used for metastatic prostate cancer can reduce pain as they shrink tumors. Bone metastases – present in around 85% of those with metastatic prostate cancer – are the primary cause of symptoms and death from metastatic prostate cancer. An alternative is the cell therapy procedure Sipuleucel-T, where the affected person's immune cells are removed, treated to more effectively target prostate cancer cells, and re-injected.
<br>